China (Mainland)
Semaglutide 99% (recombinant) CAS NO.910463-68-2
- FOB Price: USD: 1.00-1.00 /Kilogram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C,T/T
- Available Specifications:
for tablets(1-10)Kilogramfor injection(1-10)Kilogram
- Product Details
Keywords
- Semaglutide
- Ozempic
- Diabetes
Quick Details
- ProName: Semaglutide 99% (recombinant)
- CasNo: 910463-68-2
- Molecular Formula: C187H291N45O59
- Appearance: White or almost white powder
- Application: It is used for the treatment of type I...
- DeliveryTime: 7 days after receive payment
- PackAge: Double layer polyethylene bag , single...
- Port: Any port in China
- ProductionCapacity: 100 Kilogram/Year
- Purity: 99
- Storage: Store in dry dark and ventilated place
- Transportation: by Express delivery
- LimitNum: 100 Gram
- Related Substances: <=5.5%
- Residue on Ignition: N/A
- Heavy Metal: N/A
- Valid Period: N/A
- pH: 6-9
- 高分子蛋白: <=0.3%
- 水分: <=10.0%
- 宿主蛋白残留: <=100 ppm
- 宿主DNA残留: <=10 ng/mg
- 细菌内毒素: <=10 IU/mg
- 微生物限度: <=100 CFU/g
- 生物活性: 0.7-1.3 Units/mg
Superiority
Purity：>99% (for injection), >98% (for tablets)
Label: Recombinant and synthesis peptide drug substance and formulation developer
Available capacity: 13,000 m2 R&D labs, 200+ R&D staff, 40+ HPLCs and GCs, mass spectrometers including Agilent TOF, Thermo QE, AB 6500+，100 kg/a semaglutide
Further capacity: 500 kg/a (20,000L fermenter scale) in 2024
Performance: 100+ projects transferred
Technology development platform: 10+, including E.coli. recombinant drug; Yeast recombinant drug; synthesis peptide drug; Protein characterization and analysis; peptide injection; peptide tablets, etc.
Regulation: Follow FDA cGMP, FDA inspection 6 times and all passed
DMF filing: 20+ FDA DMF filing
1. High quality under strict QC/QA system with GMP factory price
2. Fast and safe delivery with secure and discreet shipment (We have experience in exporting Pharmaceutical intermediates)
3. We could provide complete manufacturer's documents for registration and filing.
( *Still in patent, so only for R&D use )
Details
Indications:
1. An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .
2. To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
3. May help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to help them lose weight and keep the weight off.
Mechanism of Action:
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.
GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors.
( *Still in patent, so only for R&D use )